Biogen's stock trading was halted due to the FDA Advisory Committee's review of LEQEMBI for early Alzheimer's disease treatment. The outcome of the review will have a direct impact on the company's stock price. A positive outcome could lead to an increase in the stock price, while a negative outcome could result in a decrease. However, since the outcome is uncertain at this point, the short-term impact is neutral.